SCHEMBL4492849

SCHEMBL4492849

CC(C)(C)OC(=O)NNC1CCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.58
GAA P10253 1/20 0.57
EPHX1 P07099 2/20 0.47
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
CTSK P43235 3/20 0.40
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
APLNR P35414 1/20 0.38
CTSS P25774 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL573789 0.96 GAA (0.61) BTKGAAEPHX1CA1CA2
SCHEMBL5287930 0.94 GAA (0.64) BTKGAAEPHX1CA1CA2
SCHEMBL5299387 0.94 GAA (0.64) BTKGAAEPHX1CA1CA2
SCHEMBL5280356 0.94 GAA (0.64) BTKGAAEPHX1CA1CA2
SCHEMBL5283385 0.94 GAA (0.64) BTKGAAEPHX1CA1CA2
SCHEMBL1863269 0.94 GAA (0.64) BTKGAAEPHX1CA1CA2
SCHEMBL2074992 0.92 GAA (0.51) BTKGAAEPHX1CA1CA2
SCHEMBL6369483 0.87 BTK (0.70) BTKGAAEPHX1CA1CA2
SCHEMBL16899726 0.87 BTK (0.70) BTKGAAEPHX1CA1CA2
SCHEMBL16899724 0.87 BTK (0.70) BTKGAAEPHX1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114716381-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114605327-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114573510-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-02-25 CN disclosed
CN-114591242-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-01-07 CN disclosed
CN-114634447-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-11-15 CN disclosed
CN-113636978-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
CN-113603645-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
US-20230301970-A1 CARBOXAMIDE DERIVATIVES NOVARTIS PHARMACEUTICALS UK LIMITED (GB) 2023-09-28 US disclosed
CN-115109032-B Quinoline derivative and application thereof in medicine 成都百裕制药股份有限公司 2023-09-05 CN disclosed
US-11672782-B2 Carboxamide derivatives NOVARTIS AG (CH) 2023-06-13 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
CN-101318962-A Fused heterocyclic compound JANSSEN PHARMACEUTICA NV (BE) 2008-12-10 CN disclosed
CN-101318961-A Fused heterocyclic compound JANSSEN PHARMACEUTICA NV (BE) 2008-12-10 CN disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed
WO-2007135417-A1 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2007-11-29 WO disclosed
CN-1882590-A Fused heterocyclic compounds as serotonin receptor modulators JOHNSON & JOHNSON (BE) 2006-12-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, PYGL, HCCS BTK 4759/4885GAA 1618/4885EPHX1 518/4885
US-20230301970-A1 CARBOXAMIDE DERIVATIVES SIRT1, ADCY5, ASIC1 BTK 1116/4885GAA 1056/4885EPHX1 2412/4885
US-11672782-B2 Carboxamide derivatives SIRT5, SIRT7, ADCY5 BTK 1004/4885GAA 919/4885EPHX1 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.